Bailard’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bailard’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,976	Closed	-$1.08M	–	800
2022 Q4	$1.08M	Hold	12,976	–	–	0.04%	250
2022 Q3	$1.03M	Hold	12,976	–	–	0.04%	242
2022 Q2	$964K	Hold	12,976	–	–	0.04%	249
2022 Q1	$1.17M	Buy	12,976 +8,467	+188%	+$782K	0.04%	248
2021 Q4	$505K	Buy	4,509 +1,449	+47%	+$175K	0.02%	405
2021 Q3	$385K	Hold	3,060	–	–	0.01%	458
2021 Q2	$414K	Buy	3,060 +60	+2%	+$7.89K	0.01%	447
2021 Q1	$407K	Hold	3,000	–	–	0.02%	434
2020 Q4	$422K	Hold	3,000	–	–	0.02%	365
2020 Q3	$334K	Hold	3,000	–	–	0.02%	360
2020 Q2	$336K	Hold	3,000	–	–	0.02%	344
2020 Q1	$232K	Sell	3,000 -60	-2%	-$5.31K	0.02%	384
2019 Q4	$291K	Hold	3,060	–	–	0.02%	417
2019 Q3	$233K	Sell	3,060 -601	-16%	-$49.9K	0.01%	446
2019 Q2	$321K	Hold	3,661	–	–	0.02%	399
2019 Q1	$331K	Buy	3,661 +60	+2%	+$5.1K	0.02%	400
2018 Q4	$258K	Hold	3,601	–	–	0.02%	445
2018 Q3	$345K	Buy	+3,601	New	+$349K	0.02%	448

Other funds holding XBI

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Bailard's XBI Position: Q1 2023 in Review

Bailard sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2023, closing a stake of 12,976 shares — an estimated $1.08M sold.

Bailard first reported a position in XBI in Q3 2018 and held it in 18 quarters. The position peaked at $1.17M in Q1 2022. 712 funds tracked by Wall St. Rank hold XBI as of Q1 2023.

Bailard reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2023 after selling out during the quarter.
Bailard sold 12,976 State Street SPDR S&P Biotech ETF shares in Q1 2023, an estimated $1.08M.
Bailard first reported a position in State Street SPDR S&P Biotech ETF in Q3 2018 and held it in 18 quarters.
Bailard's State Street SPDR S&P Biotech ETF position peaked at $1.17M in Q1 2022.
712 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2023.

Based on Bailard's 13F filing for Q1 2023, filed 8 May 2023.